InvestorWire NewsRoom

InvestorNewsBreak

InvestorNewsBreaks – KBL Merger Corp. IV’s (NASDAQ: KBLM) Special Meeting to be Held November 5, 2020, 180 Life Sciences Featured in Exclusive Broadcast
October 23, 2020

InvestorNewsBreaks – KBL Merger Corp. IV’s (NASDAQ: KBLM) Special Meeting to be Held November 5, 2020, 180 Life Sciences Featured in Exclusive Broadcast

KBL Merger Corp. (NASDAQ, KBLMKBL, KBLMR, KBLMW) (“KBL”), a special purpose acquisition company (“SPAC”) that previously announced the agreement to acquire 180 Life Sciences Corp., today announced postponement of the special meeting of its stockholders (the “Special Meeting”) to November 5, 2020. KBL determined to postpone the Special Meeting (originally scheduled for Monday, October 26, 2020) so that it better aligns with anticipated timing of the proposed business combination with 180 Life Sciences. As a result of this change, the Special Meeting will now be held at 10:00 a.m., local time, on November 5, 2020, at the offices of KBL located at 30 Park Place, Suite 64B, New York, NY 10007. Also as a result of this change, the date and time by which stockholders seeking to exercise redemption rights must tender their public shares physically or electronically and submit a request in writing that KBL redeem their public shares for cash to KBL’s transfer agent, Continental Stock Transfer & Trust Company, is being extended to 5:00 p.m. Eastern Time on November 3, 2020.

In addition, 180 Life Sciences today announced the availability of a broadcast titled “Banking on the Next Blockbuster Drug.” The broadcast covers the company’s placement in an editorial published by NetworkNewsWire (“NNW”), one of 50+ brands in the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. The piece discusses enormous amounts of time and money that pharmaceutical companies invest into the research and development of new drugs, and rare occasions when these are approved and generate more than $1 billion per year in sales, a benchmark in the industry commonly called a “blockbuster.” The piece discusses 180 Life Sciences team’s significant expertise in developing new therapeutics that were sold to big pharma for billions. Renowned for development of some of the largest-selling drugs to ever come to market, the team aims to “do it again with a pipeline of drug candidates in sequential stages of development that address large untapped markets. The founding scientists at 180 Life Sciences discovered the anti-TNF drug class that led to Remicade, the fourth all-time best-selling drug in the world.”

To view the full press release and listen to the podcast, visit https://ibn.fm/o3QpN and https://ibn.fm/OtXNT

About KBL Merger Corp. IV

KBL Merger Corp. is a blank check company that raised $115 million with the goal of identifying and acquiring a company with a strong value proposition mainly in the U.S. health care industry. KBL Merger Corp. focused on this industry due to its management’s deep experience in this large, growing segment of the U.S. economy. Marlene Krauss, MD is the CEO of KBL Merger Corp. This is Dr. Krauss’ fourth SPAC in the healthcare space. She has invested more than $1 billion through three institutional venture capital funds, numerous IPOs and three prior SPACS. For more information, visit www.KBLMerger.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).